Aripiprazole Tablet, Orally Disintegrating
Product Images NDC 72578-106

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 72578-106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Viona Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 01

Chemical structure of aripiprazole shown as a detailed molecular diagram illustrating its atomic connections and functional groups.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 02

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing aripiprazole fold change and 90% confidence intervals. It compares changes in AUC and Cmax relative to a reference without interacting drugs for various inhibitors, inducers, acid blockers, and others like ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, and lorazepam.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 03

A figure titled 'Effect of Other Drugs on Aripiprazole' showing a plot of dehydro-aripiprazole fold change with 90% confidence intervals. The y-axis lists interacting drugs by type, including CYP3A4 and CYP2D6 inhibitors and inducers, gastric acid blockers, and others such as valproate, lithium, and lorazepam. The x-axis represents change relative to reference without interacting drug, ranging from 0 to 3. Data points with error bars show the effect magnitude on aripiprazole pharmacokinetics, specifically AUC and Cmax values.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 04

A chart illustrating the effect of Aripiprazole on the pharmacokinetics of various drugs, showing fold change and 90% confidence intervals. The x-axis represents the change relative to reference (without interacting drug), ranging approximately from 0.0 to 3.0, and the y-axis lists drugs affected, including CYP2D6 substrates like dextromethorphan and CYP2C9 substrates like warfarin, as well as other drugs such as omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 05

A chart titled 'Aripiprazole Fold Change and 90% CI' displaying the pharmacokinetic (PK) fold change and 90% confidence intervals for Aripiprazole under different special populations. It compares AUC and Cmax variables for CYP2D6 metabolizer status, gender, age groups, hepatic impairment severities, and severe renal impairment, showing change relative to reference values on a horizontal axis from 0.5 to 3.0 fold.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 06

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' displaying fold changes in AUC and Cmax relative to reference for various factors: CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment. The horizontal axis shows fold change from 0 to 3, with data points and error bars indicating variability.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 07

A Kaplan-Meier survival curve showing the proportion of subjects with relapse over 182 days from randomization for Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The chart includes a risk table with the number of subjects at risk at multiple time points during the study for both Aripiprazole and placebo groups.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 08

A Kaplan-Meier survival curve comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole and Placebo groups. The graph includes the number of subjects at risk at various time points for both treatment arms.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 09

A Kaplan-Meier curve depicting the proportion of subjects with relapse over 364 days from randomization, comparing Aripiprazole and placebo groups. The graph shows the number of subjects at risk at various time points and plots relapse proportions, with a lower relapse proportion trend for Aripiprazole compared to placebo.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 10

A line graph showing the change in YGTSS total tic score from baseline over 8 weeks of treatment. The graph compares three groups: Abilify Low dose, Abilify High dose, and Placebo, with the y-axis representing least-squares mean change in tic score and the x-axis representing weeks of treatment. Both Abilify groups show a greater decrease in tic score compared to placebo over time.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 11

Packaging label for Aripiprazole Orally Disintegrating Tablets USP, 10 mg strength, in a bottle of 30 tablets. Distributed by Viona Pharmaceuticals Inc. and manufactured by Square Pharmaceuticals Ltd. The label includes storage instructions, phenylketonurics warning, and a pharmacist dispensing note.*

FDA Label Image

F14d468d 36d9 4312 A2e8 E5993c0ab6ef 12

Label for Aripiprazole Orally Disintegrating Tablets, USP 15 mg, distributed by Viona Pharmaceuticals Inc. The label indicates the product contains 30 tablets and is Rx only. Manufactured by Square Pharmaceuticals Ltd., Bangladesh, it includes instructions for pharmacists and storage conditions. The design features yellow highlights and Viona's logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.